New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors

Cardiovascular Drugs and Therapy

Volumn 32, Issue 1, 2018, Pages 99-119

  Tamargo, Juan ^a   Caballero, Ricardo ^a   Delpón, Eva ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Chronic kidney disease; Heart failure; Hyperkalemia; Patiromer sorbitex calcium; Potassium binders; Renin angiotensin aldosterone inhibitors; Sodium zirconium cyclosilicate

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PATIROMER; POTASSIUM; SODIUM ZIRCONIUM CYCLOSILICATE; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; CHELATING AGENT; MINERALOCORTICOID ANTAGONIST; POLYMER; SILICATE; ZS-9 COMPOUND;

ABDOMINAL DISCOMFORT; CLINICAL OUTCOME; CONSTIPATION; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FLATULENCE; HEART ARRHYTHMIA; HEART MUSCLE EXCITABILITY; HEART REPOLARIZATION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; MEMBRANE STEADY POTENTIAL; NAUSEA; OUTCOME ASSESSMENT; POTASSIUM TRANSPORT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SMALL INTESTINE ABSORPTION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; BLOOD; CHEMICALLY INDUCED; DRUG EFFECT; HOMEOSTASIS; TREATMENT OUTCOME;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOMARKERS; CHELATING AGENTS; HOMEOSTASIS; HUMANS; HYPERKALEMIA; MINERALOCORTICOID RECEPTOR ANTAGONISTS; POLYMERS; POTASSIUM; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SILICATES; TREATMENT OUTCOME;

EID: 85040937754     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-017-6767-5     Document Type: Review

References (168)

1. Youn JH, McDonough AA. Recent advances in understanding integrative control of potassium homeostasis. Annu Rev Physiol. 2009;71:381–401.
2. Gumz ML, Rabinowitz L, Wingo C. An integrated view of potassium homeostasis. N Engl J Med. 2015;373:60–72.
3. Palmer BF. Regulation of potassium homeostasis. Clin J Am Soc Nephrol. 2015;10:1050–60.
4. Tamargo J, Caballero R, Gómez R, Valenzuela C, Delpón E. Pharmacology of cardiac potassium channels. Cardiovasc Res. 2004;62:9–33.
5. Rabelink TJ, Koomans HA, Hené RJ, Dorhout Mees EJ. Early and late adjustment to potassium loading in humans. Kidney Int. 1990;38:942–7.
6. Giebisch GH, Wingo CS. Renal potassium homeostasis: a short historical perspective. Semin Nephrol. 2013;33(3):209–14.
7. Preston RA, Afshartous D, Rodco R, Alonso AB, Garg D. Evidence for a gastrointestinal-renal kaliuretic signaling axis in humans. Kidney Int. 2015;88:1383–91.
8. Epstein M, Lifschitz MD. The unappreciated role of extrarenal and gut sensors in modulating renal potassium handling: implications for diagnosis of dyskalemias and interpreting clinical trials. Kidney Int Reports. 2016;1(1):43–56.
9. Sorensen MV, Grossmann S, Roesinger M, Gresko N, Todkar AP, Barmettler G, et al. Rapid dephosphorylation of the renal sodium chloride cotransporter in response to oral potassium intake in mice. Kidney Int. 2013;83(5):811–24.
10. Jarman PR, Mather HM. Diabetes may be independent risk factor for hyperkalemia. BMJ. 2003;327:812.
11. McCormick JA, Ellison DH. Distal convoluted tubule. Compr Physiol. 2015;5:45–98.
12. Ellison DH, Terker AS, Gamba G. Potassium and its discontents: new insight, new treatments. J Am Soc Nephrol. 2016;27:981–9.
13. Welling PA. Roles and regulation of renal K channels. Annu Rev Physiol. 2016;78(1):415–35.
14. Wang W. Regulation of renal K transport by dietary K intake. Annu Rev Physiol. 2004;66:547–69.
15. Agarwal R, Afzalpurkar R, Fordtran JS. Pathophysiology of potassium absorption and secretion by the human intestine. Gastroenterology. 1994;107:548–71.
16. Sorensen MV, Matos JE, Praetorius HA, Leipziger JL. Colonic potassium handling. Pflügers Arch Eur J Physiol. 2010;459:645–56.
17. Kamel KS, Schreiber M. Asking the question again: are cation exchange resins effective for the treatment of hyperkalemia? Nephrol Dial Transplant. 2012;27:4294–7.
18. Rechkemmer G, Frizzell RA, Halm DR. Active potassium transport across guinea-pig distal colon: action of secretagogues. J Physiol. 1996;493:485–502.
19. Mathialahan T, Maclennan KA, Sandle LN, Verbeke C, Sandle GI. Enhanced large intestinal potassium permeability in end-stage renal disease. J Pathol. 2005;206:46–51.
20. Tamargo J, Caballero R, Delpón E. New drugs for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors—hype or hope? Discov Med. 2014;18:249–54.
21. Nyirenda MJ, Tang JI, Padfield PL, Seckl JR. Hyperkalaemia. BMJ. 2009;339:b4114.
22. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169(12):1156–62.
23. Fleet JL, Shariff SZ, Gandhi S, Weir MA, Jain AK, Garg AX. Validity of the International Classification of Diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission. BMJ Open. 2012;2:e002011.
24. Chen Y, Chang AR, MA MADM, Inker LA, Matsushita K, Ballew SH, et al. Serum potassium, mortality, and kidney outcomes in the Atherosclerosis Risk in Communities Study. Mayo Clin Proc. 2016;91:1403–12.
25. Chang AR, Sang Y, Leddy J, Yahya T, Kirchner HL, Inker LA, et al. Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension. 2016;67:1181–8.
26. Kovedsky CP. Updates in hyperkalemia: outcomes and therapeutic strategies. Rev Endocr Metab Disord. 2017;18:41–7.
27. Phillips BM, Milner S, Zouwail S, Roberts G, Cowan M, Riley SG, et al. Severe hyperkalaemia: demographics and outcome. Clin Kidney J. 2014;7:127–33.
28. Paice B, Gray JM, McBride D, Donnelly T, Lawson DH. Hyperkalaemia in patients in hospital. Br Med J (Clin Res Ed). 1983;286:1189–92.
29. Acker CG, Johnson JP, Palevsky PM, Greenberg A. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med. 1998;158(8):917–24.
30. Stevens MS, Dunlay RW. Hyperkalemia in hospitalized patients. Int Urol Nephrol. 2000;32:177–80.
31. An JN, Lee JP, Jeon HJ, Kim DH, Oh YK, Kim YS, et al. Severe hyperkalemia requiring hospitalization: predictors of mortality. Crit Care. 2012;16:R225.
32. McMahon GM, Mendu ML, Gibbons FK, Christopher KB. Association between hyperkalemia at critical care initiation and mortality. Intensive Care Med. 2012;38:1834–42.
33. Khanagavi J, Gupta T, Aronow WS, Shah T, Garg J, Ahn C, et al. Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes. Arch Med Sci. 2014;2:251–7.
34. Dunn JD, Benton WW, Orozco-Torrentera E, Adamson RT. The burden of hyperkalemia in patients with cardiovascular and renal disease. Am J Manag Care. 2015;21(15 Suppl):s307–1.
35. Alfonzo A, Soar J, MacTier R, Fox J, Shillday I, Nolan J, et al. Clinical practical guidelines. Treatment of acute hyperkalaemia in adults Available: http://www.renal.org/docs/default-source/default-document-library/hyperkalaemia-guideline---march-2014.pdf. Accessed 1 September 2017
36. Sica DA. Antihypertensive therapy and its effects on potassium homeostasis. J Clin Hypertens (Greenwich). 2006;8:67–73.
37. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–327.
38. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.
39. Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol. 2004;43:155–16.
40. Ahmed A, Zannad F, Love TE, Tallaj J, Gheorghiade M, Ekundayo OJ, et al. A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J. 2007;28:1334–4.
41. Ahmed MI, Ekundayo OJ, Mujib M, Campbell RC, Sanders PW, Pitt B, et al. Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int J Cardiol. 2010;144:383–8.
42. Krogager ML, Eggers-Kaas L, Aasbjerg K, Mortensen RN, Køber L, Gislason G, et al. Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction. Eur Heart J Cardiovasc Pharmacother. 2015;1:245–5.
43. Krogager ML, Torp-Pedersen C, Mortensen RN, Køber L, Gislason G, Søgaard P, et al. Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data. Eur Heart J. 2017;38:104–11.
44. Aldahl M, Jensen AC, Davidsen L, Eriksen MA, Møller Hansen S, Nielsen BJ, et al. Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J. 2017;38:2890–6.
45. Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol. 2017;46:213–21.
46. Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med. 2000;18:721–9.
47. Aslam S, Friedman EA, Ifudu O. Electrocardiography is unreliable in detecting potentially lethal hyperkalaemia in haemodialysis patients. Nephrol Dial Transplant. 2002;17:1639–42.
48. ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Part 10.1: life-threatening electrolyte abnormalities. Circulation. 2005;112(24 Suppl I):IV121–5.
49. Freeman K, Feldman JA, Mitchell P, Donovan J, Dyer KS, Eliseo L, et al. Effects of presentation and electrocardiogram on time to treatment of hyperkalemia. Acad Emerg Med. 2008;15(3):239–49.
50. Montague BT, Ouellette JR, Buller GK. Retrospective review of the frequency of ECG changes in hyperkalemia. Clin J Am Soc Nephrol. 2008;3:324–30.
51. Indermitte J, Burkolter S, Drewe J, et al. Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients. Drug Saf. 2007;30:71–80.
52. Fang J, Madhavan S, Cohen H, Alderman MH. Serum potassium and cardiovascular mortality. J Gen Intern Med. 2000;15:885–90.
53. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.
54. Hayes J, Kalantar-Zadeh K, JL L, Turban S, Anderson JE, Kovesdy CP. Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron Clin Pract. 2012;120:c8–16.
55. Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 2012;109:1510–3.
56. Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol. 2014;34:333–9.
57. Ahn SY, Ryu J, Baek SH, Kim S, Na KY, Kim KW, et al. Incident chronic kidney disease and newly developed complications related to renal dysfunction in an elderly population during 5 years: a community-based elderly population cohort study. PLoS One. 2013;8(12):e84467.
58. Luo J, Brunelli SM, Jensen DE, Yang A. Association between serum potassium and outcomes in patients with reduced kidney function. Clin J Am Soc Nephrol. 2016;11:90–100.
59. Molnar MZ, Kalantar-Zadeh K, Lott EH, JL L, Malakauskas SM, Ma JZ, et al. Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J Am Coll Cardiol. 2014;63(7):650–8.
60. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12–S154.
61. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3:S1–S150.
62. National Institute for Health and Care Excellence (NICE). Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. National Institute for Health and Care Excellence website. http://www.nice.org.uk/guidance/cg182. Accessed 4 Sept 2017.
63. St Peter WL, Odum LE, Whaley-Connell AT. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease. Pharmacotherapy. 2013;33:496–514.
64. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.
65. Conway R, Creagh D, Byrne DG, O’Riordan D, Silke B. Serum potassium levels as an outcome determinant in acute medical admissions. Clin Med (Lond). 2015;15:239–43.
66. Goyal A, Spertus JA, Gosch K, Venkitachalam L, Jones PG, Van den Berghe G, et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA. 2012;307(2):157–64.
67. McCullough PA, Beaver TM, Bennett-Guerrero E, Emmett M, Fonarow GC, Goyal A, et al. Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management. Rev Cardiovasc Med. 2014;15:11–23.
68. Ramadan FH, Masoodi N, El-Solh AA. Clinical factors associate with hyperkalemia in patients with congestive heart failure. J Clin Pharm Therapeutics. 2005;30(3):233–9.
69. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med. 2000;109:307–14.
70. Henz S, Maeder MT, Huber S, Schmid M, Loher M, Fehr T. Influence of drugs and comorbidity on serum potassium in 15,000 consecutive hospital admissions. Nephrol Dial Transplant. 2008;23:3939–45.
71. Noize P, Bagheri H, Durrieu G, Haramburu F, Moore N, Giraud P, et al. Life-threatening drug-associated hyperkalemia: a retrospective study from laboratory signals. Pharmacoepidemiol Drug Saf. 2011;20:747–53.
72. Chang HY, YW H, Yue CS, Wen YW, Yeh WT, Hsu LS, et al. Effect of potassium-enriched salt on cardiovascular mortality and medical expenses of elderly men. Am J Clin Nutr. 2006;83:1289–96.
73. Hollander-Rodríguez JC, Calvert JF. Hyperkalemia. Am J Physician. 2006;73:283–90.
74. Kuijvenhoven MA, Haak EA, Gombert-Handoko KB, Crul M. Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia. Int J Clin Pharm. 2013;35:1099–104.
75. Ben Salem C, Badreddine A, Fathallah N, Slim R, Hmouda H. Drug-induced hyperkalemia. Drug Saf. 2014;37:677–92.
76. Weinberg JM, Appel LJ, Bakris G, Gassman JJ, Greene T, Kendrick CA, et al. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med. 2009;169:1587–94.
77. Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann JP, et al. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol. 2009;20:164–71.
78. Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, Fletcher-Rogers J, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol. 2012;7(8):1234–41.
79. Drawz PE, Babineau DC, Rahman M. Metabolic complications in elderly adults with chronic kidney disease. J Am Geriatr Soc. 2012;60(2):310–5.
80. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. 2004;43(5 Suppl 1):S1–290.
81. Latts LM, Reaven NL, Funk SE, McGaughey KJ, Adamson RT. Hyperkalemia is prevalent in patients with cardiorenal comorbidities. ISPOR 20th Annual International Meeting. 2015:PVC3. https://www.ispor.org/research_pdfs/49/pdffiles/PCV33.pdf. Accessed 4 September 2017.
82. Ahmed J, Weisberg LS. Hyperkalaemia in dialysis patients. Semin Dial. 2001;14(5):348–56.
83. Glassock RJ, Goldstein DA, Goldstone R, Hsueh WA. Diabetes mellitus, moderate renal insufficiency and hyperkalemia. Am J Nephrol. 1983;3:233–40.
84. Uribarri J, MS O, Carroll HJ. Hyperkalemia in diabetes mellitus. J Diabet Complicat. 1990;4:3–7.
85. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin–angiotensin–aldosterone system. N Engl J Med. 2004;351:585–92.
86. Epstein M, Alvarez PJ, Reaven NL, Funk SE, McGaughey KJ, Brenner MS, et al. Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2016;22(11 Suppl):s311–24.
87. Pappoe LS, Winkelmayer WC. ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: are they underutilized? Drugs Aging. 2010;27(2):87–94.
88. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33(16):2088–97.
89. Desai AS, Swedberg K, McMurray JJV, Granger CB, Yusuf S, Young JB, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM program. J Am Coll Cardiol. 2007;50:1959–66.
90. Ahuja TS, Freeman D Jr, Mahnken JD, Agraharkar M, Siddiqui M, Memon A. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol. 2000;20:268–72.
91. Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5(3):531–8.
92. Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014;7(1):51–8.
93. Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, et al. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail. 2014;7(4):573–9.
94. Sarwar CM, Papadimitriou L, Pitt B, Piña I, Zannad F, Anker SD, et al. Hyperkalemia in heart failure. J Am Coll Cardiol. 2016;68:1575–89.
95. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4:542–51.
96. Poggio R, Grancelli HO, Miriuka SG. Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism. Postgrad Med J. 2010;86:136–42.
97. Slagman MC, Navis G, Laverman GD. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease. Curr Opin Nephrol Hypertens. 2010;19:140–52.
98. Desai A. Hyperkalemia associated with inhibitors of the renin-angiotensin-aldosterone system: balancing risk and benefit. Circulation. 2008;118(16):1609–11.
99. Maddirala S, Khan A, Vincent A, Lau K. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis. Am J Med Sci. 2008;336:330–5.
100. Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther. 2012;30:e156–66.
101. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21.
102. de Denus S, Tardif J-C, White M, Bourassa MG, Racine N, Levesque S, et al. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. Am Heart J. 2006;152(4):705–12.
103. Raebel MA, Ross C, Xu S, Roblin DW, Cheetham C, Blanchette CM, et al. Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. J Gen Intern Med. 2010;25(4):326–33.
104. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135(2):73–87.
105. Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med. 2007;24(5):486–93.
106. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009;30:418–24.
107. Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ. 2012;344:e42.
108. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis. 2006;48:8–20.
109. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543–51.
110. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892–903.
111. Takahashi S, Katada J, Daida H, Kitamura F, Yokoyama K. Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis. J Hum Hypertens. 2016;30:534–42.
112. Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int. 2000;58(5):2084–92.
113. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100:1056–64.
114. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008;118:1643–50.
115. Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol. 2013;62:1585–93.
116. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail. 2004;10:297–303.
117. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17.
118. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41:211–4.
119. Shah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol. 2005;46(5):845–9.
120. Raebel MA, McClure DL, Simon SR, et al. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf. 2007;16:55–64.
121. Cooper LB, Hammill BG, Peterson ED, Pitt B, Maciejewski ML, Curtis LH, et al. Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failre. JAMA. 2015;314:1973–5.
122. Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(Suppl):S212–20.
123. US Renal Data System, USRDS. 2013 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2013.
124. Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, et al. Use of aldosterone antagonists in heart failure. JAMA. 2009;302(15):1658–65.
125. Yildirim T, Arici M, Piskinpasa S, Aybal-Kutlugun A, Yilmaz R, Altun B, et al. Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern? Ren Fail. 2012;34(9):1095–9.
126. Maggioni AP, Anker SD, Dahlström U, Heart Failure Association of the ESC, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15:1173–84.
127. Berbenetz NM, Mrkobrada M. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16:246.
128. Krantz MJ, Ambardekar AV, Kaltenbach L, Hernandez AF, Heidenreich PA, Fonarow GC, et al. Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines-Heart Failure). Am J Cardiol. 2011;107:1818–23.
129. Rassi AN, Cavender MA, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, et al. Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J Am Coll Cardiol. 2013;61:35–40.
130. Komajda M, Anker SD, Cowie MR, Filippatos GS, Mengelle B, Ponikowski P, et al. Physicians’ adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016;18(5):514–22.
131. Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017;38(24):1883–90.
132. Kovesdy CP, Regidor DL, Mehrotra R, Jing J, McAllister CJ, Greenland S, et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol. 2007;2(5):999–1007.
133. Weisberg LS. Management of severe hyperkalemia. Crit Care Med. 2008;36:3246–51.
134. Elliott MJ, Ronksley PE, Clase CM, Ahmed SB, Hemmelgarn BR. Management of patients with acute hyperkalemia. CMAJ. 2010;182:1631–5.
135. Kovesdy CP. Management of hyperkalemia: an update for the internist. Am J Med. 2015;128:1281–7.
136. Pitt B, Bakris GL. New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future. Hypertension. 2015;66:731–8.
137. Fordjour KN, Walton T, Doran JJ. Management of hyperkalemia in hospitalized patients. Am J Med Sci. 2014;347:93–100.
138. Rossignol P, Legrand M, Kosiborod M, Hollenberg SM, Peacock WF, Emmett M, et al. Emergency management of severe hyperkalemia: guideline for best practice and opportunities for the future. Pharmacol Res. 2016;113:585–91.
139. Goraya N, Wesson DE. Dietary interventions to improve outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens. 2015;24:505–10.
140. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol. 2010;21:733–5.
141. Scherr L, Ogden DA, Mead AW, Spritz N, Rubin AL. Management of hyperkalemia with a cation-exchange resin. N Engl J Med. 1961;264:115–9.
142. Mahoney BA, Smith WA, Lo DS, Tsoi K, Tonelli M, Clase CM. Emergency interventions for hyperkalaemia. Cochrane Database Syst Rev. 2005;2:CD003235.
143. Kessler C, Ng J, Valdez K, Xie H, Geiger B. The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia. J Hosp Med. 2011;6:136–40.
144. Watson MA, Baker TP, Nguyen A, Sebastianelli ME, Stewart HL, Oliver DK, et al. Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study. Am J Kidney Dis. 2012;60:409–16.
145. Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med. 2013;126:264.e9–4.
146. Kayexalate (sodium polystyrene). Bridgewater, NJ: Sanofi-Aventis US LLC. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/011287s023lbl.pdf. Last accessed 5 Sept 2017.
147. Chernin G, Gal-Oz A, Ben-Assa E, Schwartz IF, Weinstein T, Schwartz D, et al. Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy. Clin Cardiol. 2012;35(1):32–6.
148. Lepage L, Dufour AC, Doiron J, Handfield K, Desforges K, Bell R, et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clin J Am Soc Nephrol. 2015;10:2136–42.
149. Epstein M, Pitt B. Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer. Expert Opin Pharmacother. 2016;17:1435–48.
150. Weir MR, Mayo MR, Garza D, Arthur SA, Berman L, Bushinsky D, et al. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics. J Hypertens. 2017;35(Suppl 1):S57–63.
151. Veltassa™. Prescribing information. Available at: http://www.relypsa.com/veltassa/prescribing-information/. Last accessed 5 Sept 2017.
152. Buysse JM, Huang IZ, Pitt B. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Future Cardiol. 2012;8:17–28.
153. Li L, Harrison SD, Cope MJ, Park C, Lee L, Salaymeh F, et al. Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia. J Cardiovasc Pharmacol Ther. 2016;21:456–65.
154. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN Randomized Clinical Trial. JAMA. 2015;314:151–61.
155. Bushinsky DA, Williams GH, Pitt B, Weir MR, Freeman MW, Garza D, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int. 2015;88(6):1427–33.
156. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32:820–8.
157. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372:211–21.
158. Weir MR, Bakris GL, Gross C, Mayo MR, Garza D, Stasiv Y, et al. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int. 2016;90:696–704.
159. Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015;17:1057–65.
160. Packham DK, Kosiborod M. Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia. Expert Opin Drug Metab Toxicol. 2016;12:567–73.
161. Yang A, Leon A, Nuttall M, Low J, Rasmussen H. In vitro ion exchange capacity and selectivity of ZS-9, a novel, selective cation trap for the treatment of hyperkalemia. Am J Kidney Dis. 2014;63:A115.
162. + selective ion trap. PLoS One. 2014;9:e114686.
163. Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia. JAMA. 2014;312:2223–33.
164. Ash SR, Singh B, Lavin PT, Stavros F, Rasmussen HS. Safety and efficacy of ZS9, a novel selective cation trap, for treatment of hyperkalemia in patients with chronic kidney disease. Kidney Int. 2015;88(2):404–11.
165. Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015;372:222–31.
166. Kosiborod M, Peacock WF, Packham DK. Sodium zirconium cyclosilicate for urgent therapy of severe hyperkalemia. N Engl J Med. 2015;372:1577–8.
167. Anker SD, Kosiborod M, Zannad F, Piña IL, McCullough PA, Filippatos G, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail. 2015;17(10):1050–6.
168. Tumlin JA, Kosiborod M, Pergola PE, Qunibi WY, Pacham DK, Roger SD, Lerma EV, Fisbane S, Rasmussen HS, Spinowitz BS. Long-term (52-week) efficacy and safety of ZS-9 in the treatment of hyperkalemia: Interim results from a phase 3 open-label, multi-center, multi-dose maintenance study. J Am Soc Nephrol 2015;26:SA-PO1101.